Repatha dosing
Pro Research Analysisby 
Searched over 200M research papers for "repatha dosing"
Consensus Meter
Repatha Dosing: An Overview
Introduction to Repatha (Evolocumab)
Repatha, also known by its generic name evolocumab, is a fully human monoclonal antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). This drug is primarily used to manage hyperlipidemia by significantly reducing low-density lipoprotein cholesterol (LDL-C) levels in the blood .
Dosage and Administration
Standard Dosing Regimen
Repatha is administered subcutaneously and is available in two dosing regimens: 140 mg every two weeks or 420 mg once a month. These dosing options provide flexibility for patients and healthcare providers to choose a regimen that best fits the patient's lifestyle and medical needs .
Efficacy in Different Patient Populations
Clinical trials have demonstrated that evolocumab is effective in various patient populations, including those with primary hypercholesterolemia, mixed dyslipidemia, and both heterozygous and homozygous familial hypercholesterolemia. When added to statin therapy, evolocumab can reduce LDL-C levels by approximately 50-60% from baseline . It is also effective as a monotherapy in statin-intolerant patients.
Clinical Efficacy
LDL-C Reduction
Evolocumab has shown significant efficacy in reducing LDL-C levels across multiple clinical trials. In 12-week phase III trials, evolocumab reduced LDL-C levels by 54.8% to 76.3% compared to placebo and by 36.9% to 47.2% compared to ezetimibe. These reductions were observed in patients on statin therapy, those who were statin-intolerant, and those with familial hypercholesterolemia .
Long-term Efficacy and Safety
The long-term efficacy and safety of evolocumab have been confirmed in studies lasting up to 76 weeks. The drug has been well-tolerated, with no significant adverse effects reported, making it a reliable option for long-term management of hyperlipidemia .
Conclusion
Repatha (evolocumab) offers a potent and flexible option for managing hyperlipidemia, particularly in patients who are unable to achieve LDL-C targets with statins alone or who are statin-intolerant. Its dosing regimens of 140 mg every two weeks or 420 mg once a month provide effective and convenient options for patients. The drug's ability to significantly reduce LDL-C levels and its favorable safety profile make it a valuable addition to lipid-lowering therapies .
Sources and full results
Most relevant research papers on this topic